Montag & Caldwell LLC increased its position in Allergan PLC (NYSE:AGN) by 16.2% during the second quarter, Holdings Channel reports. The firm owned 687,035 shares of the company’s stock after buying an additional 95,951 shares during the period. Allergan PLC accounts for 3.2% of Montag & Caldwell LLC’s holdings, making the stock its 13th largest position. Montag & Caldwell LLC’s holdings in Allergan PLC were worth $158,767,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the company. Barnett & Company Inc. bought a new stake in Allergan PLC during the first quarter worth approximately $111,000. Ropes Wealth Advisors LLC boosted its stake in shares of Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock valued at $133,000 after buying an additional 58 shares during the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new stake in shares of Allergan PLC during the second quarter valued at approximately $125,000. Trust Co. of Vermont boosted its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the last quarter. Institutional investors own 85.19% of the company’s stock.
Allergan PLC (NYSE:AGN) traded up 1.24% on Tuesday, reaching $235.63. 2,504,125 shares of the company’s stock were exchanged. The company has a market capitalization of $93.30 billion, a PE ratio of 22.43 and a beta of 0.81. The company has a 50 day moving average price of $241.85 and a 200-day moving average price of $239.87. Allergan PLC has a 1-year low of $195.50 and a 1-year high of $322.68.
Allergan PLC (NYSE:AGN) last released its earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The company earned $3.68 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the company earned $4.41 earnings per share. Allergan PLC’s quarterly revenue was up 1.0% compared to the same quarter last year. On average, equities research analysts anticipate that Allergan PLC will post $14.00 earnings per share for the current year.
AGN has been the subject of several research reports. Sanford C. Bernstein restated an “outperform” rating and set a $335.00 price objective on shares of Allergan PLC in a research note on Thursday, June 9th. Wells Fargo & Co. restated a “buy” rating on shares of Allergan PLC in a research note on Friday, June 10th. Vetr upgraded shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $272.91 price objective for the company in a research note on Monday, June 13th. Piper Jaffray Cos. restated a “hold” rating and set a $236.00 price objective on shares of Allergan PLC in a research note on Saturday, June 18th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Allergan PLC in a research note on Saturday, June 25th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. Allergan PLC currently has a consensus rating of “Buy” and an average target price of $300.64.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.